SARS-CoV-2-specific T cell therapy for severe COVID-19: a randomized phase 1/2 trial.
Papadopoulou A, Karavalakis G, Papadopoulou E, Xochelli A, Bousiou Z, Vogiatzoglou A, Papayanni PG, Georgakopoulou A, Giannaki M, Stavridou F, Vallianou I, Kammenou M, Varsamoudi E, Papadimitriou V, Giannaki C, Sileli M, Stergiouda Z, Stefanou G, Kourlaba G, Gounelas G, Triantafyllidou M, Siotou E, Karaglani A, Zotou E, Chatzika G, Boukla A, Papalexandri A, Koutra MG, Apostolou D, Pitsiou G, Morfesis P, Doumas M, Karampatakis T, Kapravelos N, Bitzani M, Theodorakopoulou M, Serasli E, Georgolopoulos G, Sakellari I, Fylaktou A, Tryfon S, Anagnostopoulos A, Yannaki E.
Papadopoulou A, et al. Among authors: tryfon s.
Nat Med. 2023 Aug;29(8):2019-2029. doi: 10.1038/s41591-023-02480-8. Epub 2023 Jul 17.
Nat Med. 2023.
PMID: 37460756
Clinical Trial.